Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662895 | 0.82 | MEN1 (0.46) | SLC6A4KDM1ASRD5A2SRD5A1MEN1 | |
| SCHEMBL4663183 | 0.80 | MCHR1 (0.48) | MCHR1SRD5A2SRD5A1NPC1RAB9A | |
| SCHEMBL4664771 | 0.80 | RHEB (0.48) | SLC6A4KDM1ASRD5A2SRD5A1MEN1 | |
| SCHEMBL5902002 | 0.79 | MCHR1 (0.47) | MCHR1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4663138 | 0.79 | GCK (0.45) | SLC6A4KDM1ASRD5A2SRD5A1MEN1 | |
| SCHEMBL4663154 | 0.78 | PTGER1 (0.40) | SLC6A4KDM1ASRD5A2SRD5A1MEN1 | |
| SCHEMBL15112139 | 0.76 | BRD4 (0.39) | MCHR1TLR7ACACB | |
| SCHEMBL34475846 | 0.74 | MAOB (0.43) | SLC6A4KDM1ASRD5A2SRD5A1MEN1 | |
| SCHEMBL30501926 | 0.73 | TNF (0.47) | MEN1KMT2ATLR7 | |
| SCHEMBL18372654 | 0.73 | TNF (0.47) | MEN1KMT2ATLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1575924-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA Pharma AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004054984-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | MCHR1 2115/4885SLC6A4 2893/4885KDM1A 1161/4885 |
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | GIPR, VIP, SI | MCHR1 2432/4885SLC6A4 755/4885KDM1A 1748/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | MCHR1 3175/4885SLC6A4 1935/4885KDM1A 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.